HUP0003924A2 - Génterápiás megközelítések ApoA-I agonisták biztosítására, valamint ezek alkalmazása diszlipidémiás rendellenességek kezelésében - Google Patents

Génterápiás megközelítések ApoA-I agonisták biztosítására, valamint ezek alkalmazása diszlipidémiás rendellenességek kezelésében

Info

Publication number
HUP0003924A2
HUP0003924A2 HU0003924A HUP0003924A HUP0003924A2 HU P0003924 A2 HUP0003924 A2 HU P0003924A2 HU 0003924 A HU0003924 A HU 0003924A HU P0003924 A HUP0003924 A HU P0003924A HU P0003924 A2 HUP0003924 A2 HU P0003924A2
Authority
HU
Hungary
Prior art keywords
apoa
agonists
gene therapy
therapy approaches
apolipoprotein
Prior art date
Application number
HU0003924A
Other languages
English (en)
Inventor
Klaus Buttner
Isabelle Cornut
Jean-Louis Dasseux
Jean Dufourcq
Günther Metz
Renate Sekul
Original Assignee
Klaus Buttner
Isabelle Cornut
Jean-Louis Dasseux
Jean Dufourcq
Günther Metz
Renate Sekul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaus Buttner, Isabelle Cornut, Jean-Louis Dasseux, Jean Dufourcq, Günther Metz, Renate Sekul filed Critical Klaus Buttner
Publication of HUP0003924A2 publication Critical patent/HUP0003924A2/hu
Publication of HUP0003924A3 publication Critical patent/HUP0003924A3/hu
Publication of HU225821B1 publication Critical patent/HU225821B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Atalálmány tárgyát génterápiás megközelítések képezik, amikkel atermészetes apolipoprotein A-I (ApoA-I) agonisták természetesformáinak, azaz az érett ApoA-I-nek és preproApoA-I-nek, az ApoA-Ipeptideknek, az ApoA-I agonistáknak és szuperagonistáknak a módosítottformáit, a természetes ApoA-I aktivitását utánzó vagy meghaladópeptideket, valamint a természetes ApoA-I kódoló nukleotid-szekvenciákat lehet biztosítani, a diszlipoproteinémiához kapcsolódóbetegségek - beleértve a keringési betegségeket, az atheroszklerózist,a resztenózist, hiperlipidémiát, valamint más megbetegedéseket, mintpéldául az aszeptikus sokkot - kezelésére. Ó
HU0003924A 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders HU225821B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020329 WO1999016409A2 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Publications (3)

Publication Number Publication Date
HUP0003924A2 true HUP0003924A2 (hu) 2001-01-29
HUP0003924A3 HUP0003924A3 (en) 2005-12-28
HU225821B1 HU225821B1 (en) 2007-10-29

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003924A HU225821B1 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Country Status (17)

Country Link
US (4) US6518412B1 (hu)
EP (1) EP1039934B1 (hu)
JP (1) JP2003525565A (hu)
KR (1) KR100650975B1 (hu)
CN (1) CN100345588C (hu)
AT (1) ATE323510T1 (hu)
AU (1) AU758307B2 (hu)
CA (1) CA2304814A1 (hu)
DE (1) DE69834267T2 (hu)
ES (1) ES2263221T3 (hu)
HU (1) HU225821B1 (hu)
IL (1) IL135324A0 (hu)
NO (1) NO20001601L (hu)
NZ (1) NZ503720A (hu)
PL (1) PL193662B1 (hu)
RU (1) RU2222545C2 (hu)
WO (1) WO1999016409A2 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
JP2004500105A (ja) * 2000-03-13 2004-01-08 アムジエン・インコーポレーテツド Ｔ細胞シグナル伝達のアポリポタンパク質−ａ−１調節
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2005068020A1 (en) * 2004-01-02 2005-07-28 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
DE602005021534D1 (de) 2004-10-15 2010-07-08 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
AU2005314043A1 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2537526A1 (en) * 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
WO2007149355A2 (en) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
EP2081953A2 (en) * 2006-08-17 2009-07-29 The UAB Research Foundation Immunogenic pcpa polypeptides and uses thereof
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
PT2396017E (pt) 2009-02-16 2015-10-22 Cerenis Therapeutics Holding Sa Miméticos da apolipoproteína a-i
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
TW201215394A (en) 2010-08-30 2012-04-16 Hoffmann La Roche Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
DK2767546T3 (en) * 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
CA2838070A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (hu) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
EP0644897B1 (en) 1992-06-12 1998-09-16 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
AU695618B2 (en) * 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
KR20010030806A (ko) 2001-04-16
ATE323510T1 (de) 2006-05-15
EP1039934B1 (en) 2006-04-19
US20080050351A1 (en) 2008-02-28
US6844327B2 (en) 2005-01-18
WO1999016409A2 (en) 1999-04-08
EP1039934A1 (en) 2000-10-04
JP2003525565A (ja) 2003-09-02
US7250407B2 (en) 2007-07-31
US6518412B1 (en) 2003-02-11
NO20001601L (no) 2000-05-26
AU9671498A (en) 1999-04-23
US20030208059A1 (en) 2003-11-06
RU2222545C2 (ru) 2004-01-27
PL193662B1 (pl) 2007-03-30
NO20001601D0 (no) 2000-03-28
AU758307B2 (en) 2003-03-20
IL135324A0 (en) 2001-05-20
EP1039934A4 (en) 2002-11-27
HU225821B1 (en) 2007-10-29
PL358529A1 (en) 2004-08-09
CA2304814A1 (en) 1999-04-08
CN100345588C (zh) 2007-10-31
HUP0003924A3 (en) 2005-12-28
CN1303298A (zh) 2001-07-11
NZ503720A (en) 2002-10-25
US20050148513A1 (en) 2005-07-07
DE69834267T2 (de) 2007-01-04
KR100650975B1 (ko) 2006-11-29
ES2263221T3 (es) 2006-12-01
DE69834267D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
HUP0003924A2 (hu) Génterápiás megközelítések ApoA-I agonisták biztosítására, valamint ezek alkalmazása diszlipidémiás rendellenességek kezelésében
HUP0103114A2 (hu) Apolipoprotein A-1 agonisták és alkalmazásuk diszlipidémiás rendellenességek kezelésében
NO20001600L (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
NO20001599D0 (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE255635T1 (de) Polypeptid, fähig zur inhibierung der bindung zwischen menschliches il-6 und dessen rezeptor
ZA99133B (en) Transgenic rabbit that expresses a functional human lipoprotein (A).
DE69434218D1 (de) Photodynamische behandlung von synovium
BR0015533A (pt) Iduronidase-alfa-l recombinante, métodos para sua produção e purificação e métodos para tratamento de doenças causadas por deficiências da mesma
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
BR9910323A (pt) Alfa-l-iduronidase recombinante, métodos para produção e purificação da mesma e métodos para tratamento de doenças ocasionadas deficiência da mesma
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
HUP0202166A2 (hu) Bakteriális patogén gének globális szabályzói: bakteriális autoindukálószer-inaktiváló fehérje, és alkalmazása betegség elleni rezisztenciát kiváltó, géntechnológiai módosításokra
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten
YU8395A (sh) Protein sa tpo aktivnošću